Mater Pathology

Improved polymerase chain reaction (PCR) testing for Gonococcus and Chlamydia

February 16, 2011

Mater Pathology has introduced an exciting new technological upgrade in testing for Chlamydia and Gonorrhoea PCR—the Viper XTR™.

Based on polymerase chain reaction technology (as with the superseded ProbeTec system), technological improvements have resulted in an assay with increased specificity and a zero incidence of equivocal results. This means that such tests will not need to be repeated resulting in a shorter turn-around time. Another benefit of the new test system is that it is not affected by sample inhibition related to blood, lubricants or fluorescent dyes.

The Viper™ assay has been cleared by the Food and Drug Administration (FDA) for the broadest range of collection types of any assay on the market including; cervical swabs, urethral swabs, physician and self collected high vaginal swabs, Surepath and Thinprep LBC vials and urine samples for both symptomatic and asymptomatic patients.

The Viper XTR™ specimen collection system has been improved as well. Mater Pathology will be replacing the old pink endocervical and blue male urethra swabs with female endocervical and male urethral specimen collection kits. While the old swabs can still be tested in the Viper XTR™ system, the new swabs are supplied with an easy to use transport medium that ensures specimen stability for up to 30 days at a wide range of temperatures (2 to 30˚C).

For further information, please contact:

Microbiology Laboratory, Mater Pathology
07 3163 8168